summit astrazeneca - Search News

News

AstraZeneca, Lung cancer and Summit Therapeutics

Summit, AstraZeneca in talks over $15 billion cancer drug licensing deal, Bloomberg News reports

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar with the matter.

The Pharma Letter · 16h

AstraZeneca in talks with Summit for over $15 billion license deal

UK pharma major AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar with the matter.

Benzinga · 1d

AstraZeneca In $15 Billion Talks For Drug That Could Upend Lung Cancer Treatment

AstraZeneca is in advanced talks with Summit Therapeutics over a potential $15 billion deal for the lung cancer drug ivonescimab.

16h

Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

1don MSN

Why Summit Therapeutics Stock Soared 8% Higher Today

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

STAT1mon

ASCO 2025: Pfizer, AstraZeneca, Daiichi Sankyo, Summit

At ASCO Day 1, Summit Therapeutics crashes the party again, Pfizer's drug demonstrates "unprecedented" survival rate, and more. ... AstraZeneca’s plenary streak continues: ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results